Morgens Waterfall Vintiadis & Co’s Cardiff Oncology CRDF Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,167	Closed	-$1.35M	–	52
2016 Q3	$1.35M	Hold	4,167	–	–	1.18%	35
2016 Q2	$1.36M	Sell	4,167 -6,458	-61%	-$2.22M	1.26%	29
2016 Q1	$3.56M	Sell	10,625 -347	-3%	-$118K	2.47%	6
2015 Q4	$4.27M	Hold	10,972	–	–	1.78%	14
2015 Q3	$4.5M	Buy	10,972 +347	+3%	+$182K	2.48%	9
2015 Q2	$7.76M	Buy	10,625 +2,292	+28%	+$1.63M	4.89%	4
2015 Q1	$4.09M	Buy	8,333 +3,125	+60%	+$1.33M	2.62%	14
2014 Q4	$1.61M	Buy	+5,208	New	+$1.69M	0.9%	29

Other funds holding CRDF

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's CRDF Position: Q4 2016 in Review

Morgens Waterfall Vintiadis & Co sold out of Cardiff Oncology (CRDF) in Q4 2016, closing a stake of 4,167 shares — an estimated $1.35M sold.

Morgens Waterfall Vintiadis & Co first reported a position in CRDF in Q4 2014 and held it in 8 quarters. The position peaked at $7.76M in Q2 2015. 68 funds tracked by Wall St. Rank hold CRDF as of Q4 2016.

Morgens Waterfall Vintiadis & Co reported no remaining Cardiff Oncology position as of Q4 2016 after selling out during the quarter.
Morgens Waterfall Vintiadis & Co sold 4,167 Cardiff Oncology shares in Q4 2016, an estimated $1.35M.
Morgens Waterfall Vintiadis & Co first reported a position in Cardiff Oncology in Q4 2014 and held it in 8 quarters.
Morgens Waterfall Vintiadis & Co's Cardiff Oncology position peaked at $7.76M in Q2 2015.
68 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2016.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q4 2016, filed 19 Jan 2017.